Biotheus Inc.
20
7
12
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 20 trials
10%
2 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (20)
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Role: collaborator
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Role: collaborator
PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Role: lead
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC
Role: lead
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
Role: lead
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
Role: lead
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
Role: lead
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
Role: lead
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
Role: lead
A Study of PM8002 in Combination With Chemotherapy in Patients With NEN
Role: lead
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
Role: lead
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
Role: lead
PM8002 in the Treatment of Patients With Advanced Solid Tumors
Role: lead
A Study of PM1015 in Patients With Advanced Solid Tumors
Role: lead
A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM
Role: lead
A Study of PM1022 in Patients With Advanced Tumors
Role: lead
Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors
Role: lead
Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors
Role: lead
A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours
Role: lead
A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours
Role: lead
All 20 trials loaded